Published adherence literature using pharmacy databases is based on data from patients who have 1 or more dispensings of the drug(s) of interest. 2 ,6,8.12,14. 16 By definition , pharmacy claims databases do not contain information about medications ordered but neverdispensed (ie, primary nonadherence). Furthermore, medications dispensed BACKGROUND: Many medicat ion adherence metrics are based on refill rates determ ined from pharmacy claims databases. However, these methods do not incorporate assessment of nonadherence to new prescr iptions when those prescr iptions are never dispensed (primary nonadherence), or dispensed only once (early nonpe rsistence). As a result . published studies may overestimate adherence. but the extent of overes timat ion posed by not cons idering patients with primary nonadherence and early nonpersistence has not been assessed.
A dherence to medications is directly associated with improved clinical outcomes in chronic diseases such as diabetes, heart failure,hyperlipidemia, coronary artery disease, and hypertension."? High adherence is also associated with lower health care costs." If adherence is inaccurately estimated, results of comparative effectiveness research may not be correctly interpreted, as the relationship between medication exposureand clinical outcome is likely to be distorted.
Adherence is often calculated using claims-based electronic pharmacy databases/ :" Pharmacy databases enable adherence monitoring in large populations andassess medication dispensing, thecritical first step in the adherence process. Pharmacy databases have also been used to trigger interventions intended to increase medication effectiveness and safety," Claims databases are extensively used to estimate adherence because they arerelatively inexpensive, efficient, andan accessible source of information about the frequency andtimeliness of medication refills in largepopulations.P A key limitation to pharmacy databases is that they can beused onlyto estimate medication possession, notmedication consumption. Other tools to measure adherence, such as electronic devices, patient self-report, and pillcounts, have advantages and disadvantages; no methodis considered the gold standard.'
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The Annals ofPharmacotherapy • 2011 Septemb er, Volume 45 • 1053 only once but neverrefilled (ie,early nonpersistence) do not meetthe minimum criterion of 2 dispensings required to calculateindices such as the continuous multiple-interval measure of gaps (CMG, the total number of days for which a drug is unavailable within a period) or the continuous multiple-interval measureof medication availability (CMA, the days' supply of medication obtainedthroughout the period divided by the number of daysof participation). 14,17.19 As a result,manyadherence studies systematically exclude patients with primary nonadherence or early nonpersistence, the 2 subcategories thattogether compose earlynonadherence.
In addition, medication ordering and dispensing are generally recorded in separate, unlinked computer systems, thus limiting access to information required to calculate early nonadherence. Prescription orders have seldombeen linked to medication dispensings, and reconciliation of orders and dispensings has been even less frequent. We must better understand the importance of excludingcalculations of early nonadherence and the implications this has on interpreting comparative effectiveness data if we are to achieve the full benefits of adherenceand comparativeeffectiveness initiatives.
We hypothesizedthat populationmedicationadherence estimates calculated from pharmacy databases are inflated as a result of excluding datafrom patients who fail to obtain initial prescriptions for chronic medications and patientswho obtainonly a singledispensing of chronicmedications. Our specific objective was to estimate the magnitude of misestimation in adherence estimatesthat resultedfrom excluding assessment of patients withearly nonadherence. To achieve thisobjective, we linked prescription orders in an ambulatory electronic health record (EHR) to medication dispensings in a pharmacy information system for 3 categories of commonly used oral medication whereadherence is directly associated with improved clinical outcomes: antihypertensives, antidiabetics,and/orantihyperlipidemics.w'-" We then determined the misestimation of adherence thatresulted from not including theearlynonadherent patients.
Methods

STUDY SETTING AND POPULATION
This study was conducted at Kaiser Permanente Colorado (KPCO), a not-for-profit integratedhealth care system. The study cohort included all KPCO members in the Denver-Boulder area with a newly initiated (index) order for an oral antihypertensive, antidiabetic, or antihyperlipidernic medication between January 1,2007, and June 30, 2008. Inclusion criteria were enrollment with a pharmacy benefitfor 365 days beforeand 180days after the order;no previous order for a drug for the same therapeutic indication within 365 days prior to the initialorder; and either at least 2 coded diagnoses at least 1 month apart corresponding to an appropriate diagnosisfor the order (hypertension ICD9 codes401.0-405.9; diabetesICD9 codes 250.##,hyperlipidemia ICD9 codesfor hyperlipidemia 272.##) or the diagnosis associated with the prescription order. This study was approved by the KPCO Institutional Review Board, and the requirement for informedconsent was waived.
IDENTIFICATION OF PRESCRIPTION ORDERS AND
DISPENSINGS
Index orders were identifiedfrom the EHR medication order table. If a revised order was entered within 30 days of the initial order and the initial order had not been dispensed, the subsequent revised order was chosen as the definitive order. Prescriptions clearly not intended for chronic use were excluded (eg, perioperative~-bl ocker prescriptions for <30 totaldays).
From the EHR medicationorders table, we determined whether a prescription was designated for dispensing at a pharmacy internal or external to the KPCO system. Prescription orders intended to be dispensed at an internal pharmacyare routedelectronically to the KPCO pharmacy information management system (PIMS) using an established interface. For orders to be dispensed at an external pharmacy, the ordering clinician indicates "external dispense" in the EHR order.During the study period,approximately 95% of orders were routed internally. For orders routed internally, we determined from PIMS whether and when the medication was dispensed. Medication orders and dispensings were linked using unique patient identifiers as well as drug identifiers and date.
For drug identification, a comprehensive drug name listing within each medication class was assembled througha look-up table cross-referenced by drug name and national drug code (NDC).For internal orders,the dispensing dates, strength, formulation, instructions for use, days' supply, and NDC were ascertained.
ADHERENCE ASSESSMENT
Patients were stratified into patient drug adherence groupsbased on the following definitions:
1. Primary nonadherence: did not pickup the prescription for the newlyinitiated medication at a KPCO pharmacy and did not have it transferred to a pharmacy externalto KPCOwithin 30 days afterthe order. 2. Early nonpersistence: picked up the initial prescription for the newly initiated medication at a KPCO pharmacy within 30 days after the order but did not have it refilled or transferredto a pharmacy external to KPCO within 180days after initialdispensing. 3. Ongoing dispensing: picked up the first prescription for the newly initiated medication at a KPCO pharmacy within 30 days after the order and had the prescription refilled at least once at a KPCO pharmacy within 180days after initial dispensing.
For individuals who had prescriptions ordered for external dispensing (or transferred externally), adherence could not be estimated, as information about whether and when the prescription was filled was not available. We quantified the number and proportion of patients with prescriptions for external dispensing(n =756; 5%); these patients were not included in adherenceestimates.
Patients were analyzed in only I adherence group (ie, primary nonadherence, early nonpersistence, or ongoing dispensing) and only 1 therapeutic class (ie, antidiabetic, antihypertensive,antihyperlipidemic,or multiple drugs). Patients with newly ordered drugs from more than 1 therapeutic class (eg, an antidiabetic and an antihypertensive) at any time during the 18-month study period were classified into the multiple drugs class. Patients in the multiple drugs class were analyzed in the ongoing dispensing group if they had ongoing dispensings of any 1 of the newly ordered drugs. Because the study cohort was defined as including only patients who had not had a previous order for a drug in the same therapeutic class within the prior 365 days, if a patient had more than 1 newly initiated drug within that therapeutic class during the study period, only the first medication ordered during the study period was included.
Adherence was calculated from KPC9 pharmacy databases using the proportion of days covered (POe) method.":" To obtain the POC, the total days' supply dispensed was divided by the 180days in the observation period.Thisvalue wascapped at 1.0 andmultiplied by 100 to obtainpercent adherence. The POCwasdetermined at thedrug classlevel so that individuals witha within-drug switch (eg, brand to generic, different generics, different dosage strengths) or an across-drug switch (eg, simvastatin to pravastatin) within the observation period wereafforded the correct POC.Wecalculated adherence bothas a continuous measure and categorically, considering patients in the ongoing dispensing groupto be nonadherent when the poe was less than 80%.The 80% cut-point is commonly used,clinicallybased,and demonstrates a reasonable balance between sensitivity and specificity," The PDC for individuals in the multiple drugs classongoing dispensing groupwascalculated basedon themostadherent drug. ThePOCfor individuals classified into the primary nonadherence group could be greaterthan zero if they pickedup theirinitialprescription, butat sometimeafterthe3D-day period usedtodefine placementin theprimary nonadherence group.
OTHER DATA SOURCES, MANAGEMENT, AND STATISTICAL
ANALYSIS
Existing administrative and clinical databases, the PIMS system, andtheEHRwereusedto ascertain allstudy data.To assess theextent of misestimation in adherence estimates, patientsin the ongoingdispensing groupwere compared with EarlyNonadherence in Estimations ofMedication Adherence patients in the primary nonadherence and early nonpersistence groups, and differences in characteristics were assessed using a "/.,2 testfor categorical variables and the Kruskal-Wallistestfor continuous variables. Alldatachecks and analyses were performed with SASversion 9.13 (SAS Institute, Cary, NC).
We considered the adherence of patients in the ongoing dispensing group as the referencegroup (Figure 1 ). Equations usedto estimate theadherence misestimation associated with omitting patients with early nonadherence from analyses areshown inFigure 1. Estimations were weighted by theproportion of patients in each adherence group. Because the standard errors for the estimates of misestimation must account for the non-independence of the groups being compared, standard errors of thebiaswere calculated using bootstrapmethods. Wecreatedthe bootstrap replications by resampling with replacement, calculating the mean POC for eachgroup.We then usedthisdistribution for the replicated statistic to calculate thestandard error. 22 A uniform observation period of 180 dayswasusedforall patients. For patients withongoing dispensing or earlynonpersistence, the observation period beganon the dispensing date (Figure2). Because no dispensing date existedfor patients withprimary nonadherence, the date thatthe observation periodbeganfor that groupwas extrapolated usingthe median number of daysbetween thedateof theorderandthe dateof thedispensing forthepatients in theother2 adherence groups. The median numberof days between the order and dispensing dates for the other2 groups (l day)was added to theorderdatefor patients in theprimary nonadherence group as thedaytheobservation period began forthose patients.
SENSITIVITY ANALYSES
As adherence can also be determined using an observationperiodlengthlongerthan 180days,7,12,23 we additionally determinedthe poe using 365 days to evaluate the effect that changing the observation periodlengthhad on adherenceestimates.Further, because adherence definitions in this study specifieddispensing within 30 days after the order, and a 60-day period after the order had also been applied.f we determinedthe effect of changing the adherence definition to specify dispensing within 60 days (ie,reclassifying patientswho had an initialdispensing between days 31 and 60 into a different adherence group).
Results
Of 15,417 patients witha newly initiated prescription for an antihypertensive, antidiabetic, antihyperlipidemic, or multiple medications written to be dispensed at an internal KPCO pharmacy during the study period, 1142 (7%)patients were primarily nonadherent and 3356(22%) were early nonpersistent (Table 1) . Across earlynonpersistent patients, the median (5th,95thpercentile) days' supply dispensed was60
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The Annals ofPharmacotherapy • 2011 September, Volume 45 • 1055 (30, 90) . Almost 10% of individuals newly prescribed an antidiabetic or antihyperlipidemic and about 5% of patients newly prescribed an antihypertensive or multiple drugs did not pick up their prescription within 30 days after the order (Table I) . Additional adherence characteristics are shown in Table I . The misestimation in medication adherence estimates resulting from not considering patients with early nonad-herence is shown in Table 2 . Adherence estimates were inflated when only the ongoing dispensing group was considered in estimating population adherence: for patients newly prescribed a drug for diabetes, omitting the early nonadherent patients resulted in an adherence estimate 15% higher than if the adherence of the entire population for whom the drugs were ordered had been included. Omitting patients who were early nonadherent to antihy- pertensiveand antihyperlipidemic medications contributed the greatest inflation to adherence estimates (18% for each); omitting those with new prescriptions for drugs from multiple therapeutic classes contributed a lesser, but still substantial, inflation (9%).
Both primary nonadherence and early nonpersistence contributedto misestimation (Table2). Within the individual therapeutic classes, the misestimation contributed by omitting patients in the early nonpersistence subgroupexceeded that contributedby omittingpatients in the primary nonadherence subgroupbecauseof the largerproportion of patients in the early nonpersistent subgroup (Table2).
The misestimation in adherence estimates contributed by not considering early nonadherence was similar when a 365-day observationperiod was applied,ranging from 9% for early nonadherent patients with multiple therapeutic classesto 18% for early nonadherent patients prescribed an antihyperlipidemic (not shown in table).Changing the definitionof the requireddispensing time frame to 60 days reclassified(from primary nonadherence to a differentadherence group) 14 patients(of 172)prescribed an antidiabetic, EarlyNonadherence in Estimations ofMedication Adherence 45 (of 331) prescribed an antihypertensive, 137 (of 582) prescribedan antihyperlipidemic, and 6 (of 57) prescribed drugs from multiple classes. The effect of reclassifying thesepatients was minimal,with misestimation againranging from 9% to 18% (data not shown).
Discussion
The resultsof this investigation illustrate that medication adherence estimates are substantially inflated when early nonadherentpatients are omitted from adherence calculations. In our cohort, adherence estimates were inflated by 9-18%. This work also demonstrates that nearly 1 in 3 patients newly prescribed a medication for diabetes, hyperlipidemia,andlor hypertension exhibitearly nonadherence. Adherencecalculations missing patients with early nonadherence are likely to substantially misstate the effects of adherence on associated healthoutcomes.
Our work also documents that approximately 3 times as many patientsexhibitearly nonpersistence as primarynonadherence (Table 1 ). These findings are comparable to "For persons with newly initiated drugs from more than t therapeutic class, the most adherent group was assigned (eg. if they had ongoing dispens-Ings for any of the newly prescribed drugs . lhey were placed In the ongoing group). Variables were compared across columns using t .Wilcoxon rank sum, or Kruskal·Wallis test; p values for all <0.001 . bpOC is not 0 for the primary nonadherence group because a few patients In this group eventually filled the proscription at some time after the 30· day period that was used to define primary nonadherence . Between days 31 and 60 ,14 pallents prescribed an antidiabetic. 45 patients prescribed an antihypertensivo. 137 pallents prescribed an antihyperlipidemic. and 6 patients prescribed drugs from multiple classes filled their prescriptions.
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The Annals ofPharmacotherapy • 2011September, Volume 45 • 1057 those from prior research. 16 ,24' 26 Fischer and colleagues found primary nonadherence rates of 28-31% among patients newly prescribed medications for hypertension, hyperlipidemia, and diabetes," whereas we found primary nonadherence rates of 5-10% among patients newly prescribed medications for these same indications. The prevalence of primary nonadherence observed by Fischer et al. is likelyoverestimated, as the authors used cross-linkage of e-prescriptions and paid dispensing claims to identify patients without claims," A strength of our study is that we did not rely on paid claims to identify dispensings. Our findings suggest that patients initiating drugs from different therapeutic classesprovidedifferent contributions to a comprehensive adherence picture, thusimplying thatit may not be appropriate to extrapolate adherence inflation estimates from one patientgroup or therapeutic class to another. For example,about twice as many patientsstartedon an antidiabetic or antihyperlipidemic medication exhibited primary nonadherence compared with patients initiating an antihypertensive (fable 1).The reasons for this require further study.
Because KPCO is an integrated system caring for a defined population, we could accurately identify, access, and link EHR medication orders and dispensings within inter-nal systems. In conjunction , because the rate of prescription orders transmitted to external pharmacies was defined and low, we present a comprehensive picture of adherence from which we estimate the importanceof early nonadherence. As a result, this is one of the first studies to quantify the degree of inflation of adherence estimates when measured using data gleaned from pharmacy claims databases. Some might argue that, because KPCO is an integrated system, the results of this work are generalizable only to similar systems. However, as EMR use becomes more prevalent, other systems can also accurately capture orders and dispensings, and the methods we describe here will allow estimation of early nonadherence in those settings. Further, we believe our resultsrepresenta real-world"bestcase" scenario in that some barriers to prompt prescription dispensing (ie, no convenient pharmacy, handwritten prescriptions) are absent within our setting. Our results therefore likely underestimate the degree to which misestimation is presentwhen adherenceis estimated in less-integrated care settings . One additional consideration about underestimating the degree of misestimation is that we classified patients into mutually exclusive groups; if an individual had a new medication from more than I therapeu- tic area, we assigned that individual to the ongoing dispensings group if he or she had ongoing dispensings of any of the new medications. This study was not designed to assess patient factors associated with adherence. We did not attempt to identify reasons for early nonadherence or describe characteristics that differentiated patients with early nonadherence from those with continued refills. Medication intolerance or adverse events, with subsequent medication discontinuation, likely occurred among some patients with early nonadherence. This would be reflected in estimates of early nonpersistence and would affect our estimates if the patient was subsequently initiated on a different medication for the same indication within the 180-day observation period.
1\\'0 other sources of overestimation are relevant to early nonpersistent individuals. First, the POC assumes that the patient ingests the full dispensed days' supply; if this is not the case, the bias introduced would be most pronounced in POC estimates among those with early nonpersistence. For example, if a patient with early nonpersistence stopped taking the medication after only a few days, the calculated POC would reflect a higher POC than the actual one. Second, POC is sensitive to days' supply. In this work, the median days' supply was 60. If it had been 30 days, the median POC estimates in the early nonpersistent group would have been lower. If a patient who initiated therapy had a hospital or nursing home admission within the 180-day follow-up period, the POC could have been either underestimated or overestimated.
Primary nonadherence and adherence to ongoing medications might represent different patient behaviors. It could be argued that measurements such as the POC are not intended to measure primary nonadherence and that incorporating primary nonadherence data to assess misestimation in adherence estimates is not appropriate. While we acknowledge this perspective, it does not lessen the importance of the results of our work.
This study also was not designed to assess either the contributions of provider-patient interactions or clinical outcomes. Such process and outcomes assessments will be crucial to establishingthe clinical importance of our results.
In summary, this study extends our understanding of medication adherence by addressing how omitting early nonadherence information contributes to misleading adherence estimations. Through linking medication orders and dispensings, we have added to knowledge of the accuracy and completeness of dispensing databases, proportions of patients with primary nonadherence and early nonpersistence, and adherence estimates based on pharmacy claims. We also provided preliminary information about the importance of early nonadherence that is useful to clinicians, researchers, and those who work in health care information technology as they strive to increase the efficiency of the data infrastructure for comparative effectiveness studies. el avahiode la no-adherencia a 6rdenesnuevas de rnedicamentos cuando esos medicamentos nuncafuerondispensados (no-adherencia primaria) o medicamentos que solose dispensaron una vez (no-persistencia temprana). Comoresultado de no incluiresta informaci6n, los estudios publicados puedensobreestimar el nivelde adherencia, pero la rnagnitud o extensi6n de este sobreestimado no se ha estudiado.
OBJETIVOS: Estimarla magnitud de erroren la estimaci6n de adherencia que se relaciona con no incluirlos pacientes con no-adherencia prirnaria o no-persistencia temprana. Mtrooos: Se estudi6retrospectivamente un cohortede 15,417pacientes registrados en un sistemaintegrado de cuidadode saludque recibieron nuevas prescripciones de medicamentos antihipertensivos, antidiabeticos, o antihiperlipidemicos, Se unieron los datosde 6rdenesmedicas con los datos de medicamentos dispensados. Basado en losdatosde medicamentos dispensados y la raz6nde repeticiones, se estratificaron los pacientes en 3 grupos: conno-adherencia primaria, conno-persistencia temprana y pacientes con medicamentos dispensados regularmente. La adherencia se estim6utilizando la porci6n de dfascubiertos (POC). Se estandarizaron los perfodos de observaci6n paratodoslos grupos. RESULTADOS: Se encontr6que 1,142(7.4%) de los pacientes erannoadherentes primarios, 3,356(21.8%) eran no-persistentes tempranos, y 10,919(70.8%) eran pacientes que recibfan sus medicamentos en forma pCri6dica con unpromedio (mean) PDCde 84%.El no incluir lospacientes con no-adherencia prirnaria y los de no-persistencia temprana, resultaen que los estimados de adherencia estansobreestimados entre9%-18%.
CONCLUSIONES: Cuandola adherencia a medicamentos se estimautilizando la base de datosde las reclamaciones de farmacia, los estimados de adherencia estansustancialmente infladas debidoa la no-adherencia prirnaria y a la no-persistencia temprana de pacientes queno se incluye en estoscalculos, Estos estimados incorrectos pueden implicar quepotencialmente se altere0 distorsione la verdadera relaci6n entreadherencia a medicarnentos y los resultados clfnicos obtenidos. OBJECllF: La majorite des donnees d'observancemedicamenteuse est baseesur Ie tauxde renouvellement des prescriptions contenues dansdes banquesde donnees de pharmacie. Ces methodes de calcultiennent toutefois rarement comptede l'inobservance face aux nouvelles prescriptions qui ne sontjamais remplies (inobservance primaire) ou qui ne sont remplies qu'une seulefois (non-persistance). L'objectifde cette etudeetait de quantifier la magnitude d'erreur des estimesd'observance medicamenteuse provenant de l'exclusiondes donneesd'inobservance primaireet de non-persistance. 
